BTIG Research Cuts NRx Pharmaceuticals (NASDAQ:NRXP) Price Target to $10.00

NRx Pharmaceuticals (NASDAQ:NRXP) had its price target dropped by investment analysts at BTIG Research from $25.00 to $10.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s price objective points to a potential upside of 178.94% from the company’s current price.

A number of other equities research analysts have also recently issued reports on NRXP. Weiss Ratings restated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Wednesday. Wall Street Zen upgraded shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, June 14th. HC Wainwright restated a “buy” rating and set a $45.00 price target on shares of NRx Pharmaceuticals in a research note on Monday, April 27th. D. Boral Capital reaffirmed a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a report on Tuesday, May 5th. Finally, Ascendiant Capital Markets lifted their price objective on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a research note on Monday, April 27th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $34.50.

NRx Pharmaceuticals Trading Up 16.0%

Shares of NASDAQ:NRXP traded up $0.49 during mid-day trading on Friday, reaching $3.58. The company had a trading volume of 4,609,494 shares, compared to its average volume of 1,139,122. NRx Pharmaceuticals has a one year low of $1.62 and a one year high of $5.05. The company’s 50-day moving average price is $3.91 and its 200-day moving average price is $2.91. The firm has a market cap of $129.88 million, a price-to-earnings ratio of -3.28 and a beta of 2.18.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its earnings results on Friday, May 15th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $19.43 million. On average, research analysts anticipate that NRx Pharmaceuticals will post -0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its position in NRx Pharmaceuticals by 27.9% during the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after purchasing an additional 37,598 shares during the last quarter. Vanguard Group Inc. increased its stake in NRx Pharmaceuticals by 18.3% in the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after acquiring an additional 82,781 shares during the last quarter. Two Sigma Investments LP raised its position in NRx Pharmaceuticals by 66.4% during the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after purchasing an additional 20,880 shares in the last quarter. Global Retirement Partners LLC bought a new stake in NRx Pharmaceuticals during the fourth quarter worth about $107,000. Finally, Bleakley Financial Group LLC purchased a new position in shares of NRx Pharmaceuticals in the 4th quarter worth about $318,000. Institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.